Third Quarter Un-Audited Financial Statements

For the period ended 31 March 2018



ISO 9001: 2015 Certified Company

www.acmeglobal.com

The ACME Laboratories Ltd.

Statement of Financial Position (Un-Audited)

As at 31 March 2018

ASSETS	Amount in Taka		
	As at 31-03-2018	As at 30-06-2017	
Non-Current Assets:	20,024,179,000	18,275,901,469	
Property, Plant and Equipment	19,963,029,783	18,220,229,667	
Intangible Assets	130,781	162,000	
Investment in Shares	37,914,024	32,405,390	
Investment Property	23,104,412	23,104,412	
Current Assets:	11,957,663,821	11,671,330,040	
Inventories	2,989,982,694	2,907,608,895	
Trade Receivable	1,369,937,741	1,227,081,694	
Other Receivable	12,390,371	135,275,733	
Advance, Deposits & Pre-Payments	1,680,049,936	1,434,353,400	
Advance Income Tax	2,303,983,604	2,037,434,874	
Material In Transit	555,929,689	492,696,854	
Term Deposit	1,081,871,275	2,054,000,000	
Cash and Cash Equivalents	1,963,518,511	1,382,878,590	
TOTAL	31,981,842,821	29,947,231,509	
EQUITY AND LIABILITIES			
-	17 /10 022 07/	16 056 277 126	
Shareholders' Equity : Share Capital	17,418,932,876 2,116,017,000	16,956,277,126 2,116,017,000	
Share Capital Share Premium	5,127,599,728	5,127,599,728	
Revaluation Surplus	5,423,977,564	5,487,674,207	
Gain/(Loss) on Marketable Securities (Unrealized)	11,742,166	6,233,532	
Tax Holiday Reserve	179,464,241	179,464,241	
Retained Earnings	4,560,132,177	4,039,288,418	
Non Current Liabilities:	4,199,677,665	3,675,912,676	
Long Term Loan- Net off Current Maturity	3,477,954,822	3,025,882,035	
Provision For Gratuity	296,376,775	268,364,985	
Deferred Tax Liability	425,346,068	381,665,656	
Current Liabilities:	10,363,232,280	9,315,041,707	
Loans & Overdrafts	5,709,883,176	5,304,039,335	
Current Maturity of Long Term Loans	2,132,874,354	1,791,905,667	
Trade Payable	177,529,245	211,268,759	
Provision for Income Tax	2,164,813,325	1,804,196,185	
Liability for Expenses and Others	161,230,292	201,024,941	
Dividend Payable	16,901,888	2,606,820	
TOTAL	31,981,842,821	29,947,231,509	
Net Asset Value Per Share (NAVPS)	82.32	80.13	
:	02.32		

Sd/-Company Secretary Sd/-Chief Financial Officer Sd/-Deputy Managing Director Sd/-Managing Director Sd/-Meeting Chairman

(3) The ACME Laboratories Ltd.

Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)

For the period ended 31 March 2018

(Amount in Taka)

	Nine Month Ended		Third Quarter Ended	
PARTICULARS	July'17 to March'18	July'16 to March'17	January'18 to March'18	January'17 to March'17
Revenue	10,901,528,597	9,769,856,083	3,659,320,945	3,285,964,068
Less: Cost of Goods Sold	6,641,283,249	5,925,598,465	2,222,955,064	1,976,410,223
Gross Profit/(loss)	4,260,245,348	3,844,257,618	1,436,365,881	1,309,553,845
Add: Other Income	74,754,716	154,078,436	20,602,845	24,364,155
	4,335,000,064	3,998,336,054	1,456,968,726	1,333,918,000
Less: Selling, Marketing and Distribution Expenses	1,426,731,081	1,254,959,226	486,813,874	401,810,381
	2,908,268,983	2,743,376,828	970,154,852	932,107,619
Less: Administrative Expenses	472,347,669	380,638,651	164,419,096	134,184,490
	2,435,921,314	2,362,738,177	805,735,756	797,923,129
Less: Financial Expenses	753,768,165	765,837,044	273,650,405	246,268,739
Profit Before Contribution to WPPF and WWF	1,682,153,149	1,596,901,133	532,085,351	551,654,390
Less: Contribution to WPPF and WWF	80,102,531	76,042,911	25,337,398	26,269,257
Net Profit Before Tax	1,602,050,618	1,520,858,222	506,747,953	525,385,133
Less: Current Tax Expenses	360,617,140	365,703,129	100,882,836	131,346,283
Less: Deferred Tax (Income)/Expenses	43,680,412	8,946,757	14,423,373	9,144,107
Net Profit After Tax	1,197,753,066	1,146,208,336	391,441,744	384,894,743
Other Comprehensive Income				
Gain/(loss) on Marketable Securities (Unrealized)	5,508,634	3,194,274	(173,386)	3,614,295
Total Comprehensive Income for the Period	1,203,261,700	1,149,402,610	391,268,358	388,509,038
Earnings Per Share (on the Equity share of Tk. 10 each)	5.66	5.42	1.85	1.82

Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Company Secretary Chief Financial Officer Deputy Managing Director Managing Director Meeting Chairman



Statement of Changes in Equity (Un-Audited)

For the period ended 31 March 2018

(Amount in Taka)

Particulars	Share Capital	Share Premium	Revaluation Surplus	Gain/(loss) on Marketable Securities (Unrealized)	Tax Holiday Reserve	Retained Earnings	Total
Balance as at July 01, 2017	2,116,017,000	5,127,599,728	5,487,674,207	6,233,532	179,464,241	4,039,288,418	16,956,277,126
Net Profit After Tax for the period ended 31 March 2018	-	-	-	-	-	1,197,753,066	1,197,753,066
Final Dividend for the year 2016-17	-	-	-	-	-	(740,605,950)	(740,605,950)
Gain/(loss) on Marketable Securities (Unrealized)	-	-	-	5,508,634	-	-	5,508,634
Adjustment for Depreciation on Revaluation Surplus	-	-	(63,696,643)	-	_	63,696,643	-
Balance as at 31 March 2018	2,116,017,000	5,127,599,728	5,423,977,564	11,742,166	179,464,241	4,560,132,177	17,418,932,876
Balance as at 31 March 2017	2,116,017,000	5,127,599,728	5,578,555,141	5,448,929	179,464,241	3,766,183,602	16,773,268,641

Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- Company Secretary Chief Financial Officer Deputy Managing Director Managing Director Meeting Chairman

3 The ACME Laboratories Ltd.

Statement of Cash Flows (Un-Audited)

For the period ended 31 March 2018

PARTICULARS	Amount in Taka			
	July'17 to March'18	July'16 to March'17		
Cash Flows From Operating Activities:				
Collection from Sales and others	10,955,814,073	9,766,227,665		
Payment to Suppliers & Others	(8,405,326,775)	(7,619,813,048)		
Payment to WPPF and WWF	(91,599,771)	(63,094,548)		
Cash generated from operation	2,458,887,527	2,083,320,069		
Financial Expenses	(752,419,969)	(764,782,872)		
Income Tax Paid	(266,548,730)	(221,867,082)		
Net Cash Generated from Operating Activities	1,439,918,828	1,096,670,115		
	2,100,000	-,000 0,000 0,		
Cash Flows From Investing Activities:				
Acquisition of Property, Plant & Equipments	(2,304,480,620)	(1,310,009,112)		
Term Deposit	972,128,725	1,575,000,000		
Sale Proceeds of Property, Plant & Equipments	-	4,500,000		
Dividend received	498,555	372,920		
Investment in Shares	-	(6,382,371)		
Net Cash used in Investing Activities	(1,331,853,340)	263,481,437		
Cash Flows From Financing Activities:				
Dividend Paid	(726,310,882)	(768,874,021)		
Net Increase / (Decrease) in Loans and Overdrafts	405,843,841	(353,121,566)		
Net Increase / (Decrease) in Long Term Borrowings	793,041,474	(108,004,261)		
Net Cash Generated/(used) from Financing Activities	472,574,433	(1,229,999,848)		
Increase/(Decrease) in Cash and Cash Equivalents	580,639,921	130,151,704		
Cash and Cash Equivalents at the Opening	1,382,878,590	1,148,110,610		
Cash and Cash Equivalents at the Closing	1,963,518,511	1,278,262,314		
Net Operating Cash Flow Per Equity Share (NOCFPS)	6.80	5.18		

Sd/-Company Secretary Sd/-Chief Financial Officer Sd/-Deputy Managing Director Sd/-Managing Director Sd/-Meeting Chairman

3 Che ACME Laboratories Ltd.

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 31 March 2018

1 Reporting Entity

The ACME Laboratories Ltd. was founded in the year 1954 as a Proprietorship Firm and it was converted into a Private Limited Company on 17th March 1976 vide registration no. C-4745/163 of 1975-76 under the Companies Act-1913. Further, it was converted into a public limited company on 30th November 2011.

2 Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Annual Financial Statements for the Year ended 30 June 2017, as they provide an update of previously reported information.

These financial statements have been prepared in accordance with Framework, applicable International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by the Institute of Chartered Accountants of Bangladesh as Bangladesh Accounting Standards (BASs) and Bangladesh Financial Reporting Standards (BFRSs), Companies Act 1994, Bangladesh Securities and Exchange Rules 1987 and other relevant laws and regulations applicable in Bangladesh. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Previous period's figures have been regrouped/reclassified wherever considered necessary to confirm to current Period's presentation. Figures have been rounded off to the nearest taka, as the currency represented in these financial statements.

		Amount in Taka		
3.	Property Plant and Equipment	As at 31-03-2018	As at 30-06-2017	
	Opening Balance	21,957,564,591	20,426,204,664	
	Add: Addition (Net off Adjustment) during the Period	2,296,363,728	1,531,359,927	
	Less: Accumulated Depreciation (Net off Adjustment)	4,290,898,536	3,737,334,924	
	Carrying Value	19,963,029,783	18,220,229,667	
4.	Inventories			
	This consists of as follows:			
	Raw Materials	836,589,887	817,689,878	
	Packing Materials	549,876,598	538,976,580	
	Work-in-Process	507,685,476	497,654,654	
	Finished Goods	795,698,456	806,736,527	
	Printing & Stationery	109,124,614	87,647,739	
	Spare & Accessories	191,007,663	158,903,517	
	Total	2,989,982,694	2,907,608,895	

3 Che ACME Laboratories Ltd.

Notes to the Financial Statements (Un-Audited)

As at & for the period ended 31 March 2018

		Amount in Taka		
		As at 31-03-2018	As at 30-06-2017	
5.	Trade Receivable			
	Domestic	1,303,255,359	1,154,566,982	
	Exports	65,342,755	69,640,036	
	1	1,368,598,114	1,224,207,018	
	Foreign exchange Unrealized Gain	1,339,627	2,874,676	
		1,369,937,741	1,227,081,694	
6.	Advances, Deposits and Prepayment			
	Advances	1,475,187,443	1,262,927,483	
	Deposit	193,202,685	159,614,229	
	Prepayments	11,659,808	11,811,688	
		1,680,049,936	1,434,353,400	
7.	Cash and Cash Equivalents			
	This is made up as follows:			
	Cash in Hand	613,481,225	439,947,387	
	Cash at Bank	1,348,316,586	941,210,503	
	Cash at BO Account	1,720,700	1,720,700	
		1,963,518,511	1,382,878,590	
		Amount in Taka		
		July 17 to March 18	July 16 to March 17	
8.	Cost of Goods Sold			
	Material Consumption during the period	5,246,673,309	4,737,071,324	
	Factory Overhead	1,383,571,869	1,219,934,221	
	Cost of Production	6,630,245,178	5,957,005,545	
	Purchase of Finished Goods	-	6,761,300	
	Opening Stock of Finished Goods	806,736,527	717,729,076	
	Finished Goods Available	7,436,981,705	6,681,495,921	
	Closing Stock of Finished Goods	(795,698,456)	(755,897,456)	
	Cost of Goods Sold	6,641,283,249	5,925,598,465	
9.	Selling, Marketing and Distribution Expenses			
	Salary and Allownaces	799,095,671	700,603,067	
	Depreciation and Others	627,635,410	554,356,159	
		1,426,731,081	1,254,959,226	
10.	Administrative Expenses			
	Salary and Allownaces	222,875,987	201,637,544	
	Depreciation and Others	249,471,682	179,001,107	
		472,347,669	380,638,651	